Different clinical trials studies have been completed (NCT02824133 and NCT01975701) or are still recruiting GBM patients (NCT04424966 or NCT04547855) to test the efficacy of multi-targeted receptor tyrosine kinase inhibitors, such as Anlotinib, or selective FGFR1-3 inhibitors, such as Infigratinib, in relapsed or progressed GBM patients. Here, NTRK1 is linked to glioblastoma.